Neuromyelitis Optica [clinicaltrials_resource:6cfec3845151efb0c85f26c8297d5ee9]
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) [clinicaltrials:NCT00304291]Biobank For MS And Other Demyelinating Diseases [clinicaltrials:NCT00445367]Safety and Tolerability of Rituximab in Neuromyelitis Optica [clinicaltrials:NCT00501748]clinicaltrials:NCT00904826Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct [clinicaltrials:NCT01024985]Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica [clinicaltrials:NCT01339455]Maintenance Plasma Exchange for Neuromyelitis Optica [clinicaltrials:NCT01500681]A Longitudinal Study of Neuromyelitis Optica and Transverse Myelitis [clinicaltrials:NCT01623076]clinicaltrials:NCT01759602clinicaltrials:NCT01777412A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) [clinicaltrials:NCT01892345]clinicaltrials:NCT02003144clinicaltrials:NCT02021825clinicaltrials:NCT02087813clinicaltrials:NCT02166346clinicaltrials:NCT02276963Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B [clinicaltrials:NCT02283671]clinicaltrials:NCT02398994
condition [clinicaltrials_vocabulary:condition]
Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone [clinicaltrials:NCT00004645]A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) [clinicaltrials:NCT00304291]Biobank For MS And Other Demyelinating Diseases [clinicaltrials:NCT00445367]Safety and Tolerability of Rituximab in Neuromyelitis Optica [clinicaltrials:NCT00501748]clinicaltrials:NCT00787722clinicaltrials:NCT00904826Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct [clinicaltrials:NCT01024985]Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica [clinicaltrials:NCT01339455]Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica [clinicaltrials:NCT01364246]Maintenance Plasma Exchange for Neuromyelitis Optica [clinicaltrials:NCT01500681]A Longitudinal Study of Neuromyelitis Optica and Transverse Myelitis [clinicaltrials:NCT01623076]clinicaltrials:NCT01759602clinicaltrials:NCT01777412Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. [clinicaltrials:NCT01845584]A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) [clinicaltrials:NCT01892345]clinicaltrials:NCT02003144clinicaltrials:NCT02021825Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD [clinicaltrials:NCT02028884]Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD [clinicaltrials:NCT02073279]clinicaltrials:NCT02087813clinicaltrials:NCT02166346A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders [clinicaltrials:NCT02200770]Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders [clinicaltrials:NCT02249676]clinicaltrials:NCT02276963Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B [clinicaltrials:NCT02283671]clinicaltrials:NCT02398994
condition browse [clinicaltrials_vocabulary:condition-browse]
Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone [clinicaltrials:NCT00004645]A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) [clinicaltrials:NCT00304291]Biobank For MS And Other Demyelinating Diseases [clinicaltrials:NCT00445367]Safety and Tolerability of Rituximab in Neuromyelitis Optica [clinicaltrials:NCT00501748]clinicaltrials:NCT00787722clinicaltrials:NCT00904826Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct [clinicaltrials:NCT01024985]Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica [clinicaltrials:NCT01339455]Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica [clinicaltrials:NCT01364246]Maintenance Plasma Exchange for Neuromyelitis Optica [clinicaltrials:NCT01500681]A Longitudinal Study of Neuromyelitis Optica and Transverse Myelitis [clinicaltrials:NCT01623076]clinicaltrials:NCT01759602clinicaltrials:NCT01777412Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. [clinicaltrials:NCT01845584]A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) [clinicaltrials:NCT01892345]clinicaltrials:NCT02003144clinicaltrials:NCT02021825Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD [clinicaltrials:NCT02028884]Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD [clinicaltrials:NCT02073279]clinicaltrials:NCT02087813clinicaltrials:NCT02166346A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders [clinicaltrials:NCT02200770]Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders [clinicaltrials:NCT02249676]clinicaltrials:NCT02276963Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B [clinicaltrials:NCT02283671]clinicaltrials:NCT02398994
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Neuromyelitis Optica [clinicaltrials_resource:6cfec3845151efb0c85f26c8297d5ee9]
Bio2RDF identifier
6cfec3845151efb0c85f26c8297d5ee9
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:6cfec3845151efb0c85f26c8297d5ee9
identifier
clinicaltrials_resource:6cfec3845151efb0c85f26c8297d5ee9
title
Neuromyelitis Optica
@en
type
label
Neuromyelitis Optica [clinicaltrials_resource:6cfec3845151efb0c85f26c8297d5ee9]
@en
Neuromyelitis Optica